MOTPOLY Drug Patent Profile
✉ Email this page to a colleague
When do Motpoly patents expire, and what generic alternatives are available?
Motpoly is a drug marketed by Aucta and is included in one NDA. There are three patents protecting this drug.
The generic ingredient in MOTPOLY is lacosamide. There are twenty-two drug master file entries for this compound. Fifty-eight suppliers are listed for this compound. Additional details are available on the lacosamide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Motpoly
A generic version of MOTPOLY was approved as lacosamide by ALEMBIC on March 17th, 2022.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MOTPOLY?
- What are the global sales for MOTPOLY?
- What is Average Wholesale Price for MOTPOLY?
Summary for MOTPOLY
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | MOTPOLY at DailyMed |
US Patents and Regulatory Information for MOTPOLY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aucta | MOTPOLY XR | lacosamide | CAPSULE, EXTENDED RELEASE;ORAL | 216185-001 | May 4, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Aucta | MOTPOLY XR | lacosamide | CAPSULE, EXTENDED RELEASE;ORAL | 216185-002 | May 4, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Aucta | MOTPOLY XR | lacosamide | CAPSULE, EXTENDED RELEASE;ORAL | 216185-001 | May 4, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |

